- Home
- WSHP vs HOWL Comparison
WSHP vs HOWL Comparison
Compare WSHP & HOWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WSHP | HOWL |
|---|---|---|
| Founded | 2021 | 2017 |
| Country | Jersey | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.7M | 46.7M |
| IPO Year | 2024 | 2021 |
Fundamental Metrics
Financial Performance| Metric | WSHP | HOWL |
|---|---|---|
| Price | $2.95 | $1.02 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 103.0K | ★ 460.4K |
| Earning Date | 11-24-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.40 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.59 | $0.27 |
| 52 Week High | $250.00 | $1.83 |
Technical Indicators
Market Signals| Indicator | WSHP | HOWL |
|---|---|---|
| Relative Strength Index (RSI) | 27.34 | 59.47 |
| Support Level | N/A | $0.86 |
| Resistance Level | $7.68 | $1.14 |
| Average True Range (ATR) | 0.39 | 0.05 |
| MACD | -0.22 | 0.00 |
| Stochastic Oscillator | 10.22 | 56.28 |
Price Performance
Historical ComparisonAbout WSHP WeShop Holdings Limited Class A Ordinary Shares
WeShop Holdings Ltd is a community owned social commerce platform offering shoppers shares in the company every time customers make a purchase, recommend a product or refer a new member. WeShop earns revenues from advertising on their platform and commissions on the sales through the platform.
About HOWL Werewolf Therapeutics Inc.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. It is leveraging the proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. It has one reportable segment, which focuses on the discovery and development of cancer therapeutics.